Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1636 AL 1650

Protocol of a Phase II Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease

Holper S, Watson R, Churilov L, Yates P, Lim YY, Barnham KJ, Yassi N.

J Prev Alzheimers Dis. 2023;10(4):800-809. doi: 10.14283/jpad.2023.55.

Effects of DHA on cognitive dysfunction in aging and Alzheimer's disease: The mediating roles of ApoE

Zhang X, Yuan T, Chen X, Liu X, Hu J, Liu Z.

Prog Lipid Res. 2024 Jan;93:101256. doi: 10.1016/j.plipres.2023.101256. Epub 2023 Oct 27.

Targeting memory loss with aspirin, a molecular mechanism perspective for future therapeutic approaches

Gholami M, Sadegh M, Koroush-Arami M, Norouzi S, Arismani RJ, Asadi E, Amini M, Khodayari N.

Inflammopharmacology. 2023 Dec;31(6):2827-2842. doi: 10.1007/s10787-023-01347-1. Epub 2023 Nov 4.

The effectiveness of dance movement interventions for older adults with mild cognitive impairment, Alzheimer's disease, and dementia: A systematic scoping review and meta-analysis

Tao D, Awan-Scully R, Ash GI, Pei Z, Gu Y, Gao Y, Cole A, Baker JS.

Ageing Res Rev. 2023 Dec;92:102120. doi: 10.1016/j.arr.2023.102120. Epub 2023 Nov 8.

Tackling seizures in patients with Alzheimer's disease

Tombini M, Boscarino M, Di Lazzaro V.

Expert Rev Neurother. 2023 Jul-Dec;23(12):1131-1145. doi: 10.1080/14737175.2023.2278487. Epub 2023 Dec 15.

Unlocking the therapeutic potential of natural stilbene: Exploring pterostilbene as a powerful ally against aging and cognitive decline

Dutta BJ, Rakshe PS, Maurya N, Chib S, Singh S.

Ageing Res Rev. 2023 Dec;92:102125. doi: 10.1016/j.arr.2023.102125. Epub 2023 Nov 17.

Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial

Saito S, Suzuki K, Ohtani R, Maki T, Kowa H, Tachibana H, Washida K, Kawabata N, Mizuno T, Kanki R, Sudoh S, Kitaguchi H, Shindo K, Shindo A, Oka N, Yamamoto K, Yasuno F, Kakuta C, Kakuta R, Yamamoto Y, Hattori Y, Takahashi Y, Nakaoku Y, Tonomura S, Oishi N, Aso T, Taguchi A, Kagimura T, Kojima S, Taketsuna M, Tomimoto H, Takahashi R, Fukuyama H, Nagatsuka K, Yamamoto H, Fukushima M, Ihara M; COMCID Trial Investigator Group.

JAMA Netw Open. 2023 Dec 1;6(12):e2344938. doi: 10.1001/jamanetworkopen.2023.44938.

Hypertension & dementia: Pathophysiology & potential utility of antihypertensives in reducing disease burden

Lyon M, Fullerton JL, Kennedy S, Work LM.

Pharmacol Ther. 2024 Jan;253:108575. doi: 10.1016/j.pharmthera.2023.108575. Epub 2023 Dec 3.

NeuroEPO plus (NeuralCIM(®)) in mild-to-moderate Alzheimer's clinical syndrome: the ATHENEA randomized clinical trial

Sosa S, Bringas G, Urrutia N, Peñalver AI, López D, González E, Fernández A, Hernández ZM, Viña A, Peña Y, Batista JF, Valenzuela C, León K, Crombet T, Rodríguez T, Pérez L; ATHENEA Investigators.

Alzheimers Res Ther. 2023 Dec 13;15(1):215. doi: 10.1186/s13195-023-01356-w.

Longitudinal Cognitive Decline in Alzheimer Disease Prevention Trials: A Test of Time

Castilhos RM, Snitz BE.

Neurology. 2024 Jan 23;102(2):e208067. doi: 10.1212/WNL.0000000000208067. Epub 2023 Dec 26.

The Role of TNF-α in Alzheimer's Disease: A Narrative Review

Plantone D, Pardini M, Righi D, Manco C, Colombo BM, De Stefano N.

Cells. 2023 Dec 26;13(1):54. doi: 10.3390/cells13010054.

Chitosan hydrogel nanoparticle enhance therapeutic effect of bovine umbilical mesenchymal stem cell conditioned medium on canine cognitive dysfunction or canine Alzheimer's like mediated by inhibition of neuronal apoptotic

Wihadmadyatami H, Zulfikar MA, Herawati H, Pratama DAOA, Saragih GR, Kustiati U, Handayani AN.

Open Vet J. 2023 Dec;13(12):1504-1516. doi: 10.5455/OVJ.2023.v13.i12.1. Epub 2023 Dec 31.

Circular RNAs in Alzheimer's Disease: A New Perspective of Diagnostic and Therapeutic Targets

Vakili O, Asili P, Babaei Z, Mirahmad M, Keshavarzmotamed A, Asemi Z, Mafi A.

CNS Neurol Disord Drug Targets. 2023;22(9):1335-1354. doi: 10.2174/1871527321666220829164211.

Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease

Shah AJ, Mohi-Ud-Din R, Sabreen S, Wani TU, Jan R, Javed MN, Mir PA, Mir RH, Masoodi MH.

Curr Mol Pharmacol. 2023;16(3):254-279. doi: 10.2174/1874467215666220903095837.

CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab

Nisenbaum L, Martone R, Chen T, Rajagovindan R, Dent G, Beaver J, Rubel C, Racine A, He P, Harrison K, Dean R, Vandijck M, Haeberlein SB.

Alzheimers Dement. 2023 Aug;19(8):3379-3388. doi: 10.1002/alz.12919. Epub 2023 Feb 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias